On February 29, 2024, Ancora Holdings Group LLC announced that it has issued a statement with shareholders of Elanco Animal Health Inc, stating that it has nominated Kathy Turner, Craig Wallace, James Chadwick, Andrew Clarke, Ancora stated that it is important to stress that it provided Company with a detailed analysis of its issues pertaining to corporate governance, finance, operations and product development, while also privately proposing a settlement framework that accounted for a shareholder-driven refreshment of the Board and an orderly succession process in 2025 for long-serving CEO Jeff Simmons. In addition, Ancora Holdings stated that it has released a presentation and urged the shareholders of the Company to review it. Further, Ancora Holdings stated that it intended to file a preliminary proxy statement with the Securities and Exchange Commission to be used to solicit proxies for, among other matters, the election of its slate of director nominees at the 2024 annual meeting of shareholders.